Long-term outcomes of azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML.

Short NJ, Kantarjian H, Daver N, Azevedo RS, Karrar O, DiNardo CD, Kadia T, Yilmaz M, Maroun M, Hachem M, Borthakur G, Issa GC, Shpall EJ, Popat U, Huang X, Qiao W, Nasr L, Macaron W, Abramova R, Garcia-Manero G, Konopleva M, Ravandi F

Open source

DOI: 10.1182/bloodadvances.2026019841
Published: 2026 Sep 8
Container: Blood advances
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1182/bloodadvances.2026019841,
  title = {Long-term outcomes of azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML.},
  author = {Short NJ and Kantarjian H and Daver N and Azevedo RS and Karrar O and DiNardo CD and Kadia T and Yilmaz M and Maroun M and Hachem M and Borthakur G and Issa GC and Shpall EJ and Popat U and Huang X and Qiao W and Nasr L and Macaron W and Abramova R and Garcia-Manero G and Konopleva M and Ravandi F},
  year = {2026},
  journal = {Blood advances},
  doi = {10.1182/bloodadvances.2026019841},
  url = {https://doi.org/10.1182/bloodadvances.2026019841}
}

RIS

TY  - JOUR
TI  - Long-term outcomes of azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML.
AU  - Short NJ
AU  - Kantarjian H
AU  - Daver N
AU  - Azevedo RS
AU  - Karrar O
AU  - DiNardo CD
AU  - Kadia T
AU  - Yilmaz M
AU  - Maroun M
AU  - Hachem M
AU  - Borthakur G
AU  - Issa GC
AU  - Shpall EJ
AU  - Popat U
AU  - Huang X
AU  - Qiao W
AU  - Nasr L
AU  - Macaron W
AU  - Abramova R
AU  - Garcia-Manero G
AU  - Konopleva M
AU  - Ravandi F
PY  - 2026
JO  - Blood advances
DO  - 10.1182/bloodadvances.2026019841
UR  - https://doi.org/10.1182/bloodadvances.2026019841
ER  -

APA

NJ, S., H, K., N, D., RS, A., O, K., CD, D., T, K., M, Y., M, M., M, H., G, B., GC, I., EJ, S., U, P., X, H., W, Q., L, N., W, M., R, A., G, G., M, K., & F, R. (2026). Long-term outcomes of azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML.. Blood advances. https://doi.org/10.1182/bloodadvances.2026019841

Source records

pubmed · retrieved 2026-09-25T21:27:53.746Z